Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT00546260 | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI | ||
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | ||
| NCT03397888 | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist | ||
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | ||
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | ||
| NCT01176266 | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) | ||
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study | ||
| NCT03613402 | BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes | ||
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | ||
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | ||
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT05982938 | Danicopan Early Access Program | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | ||
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT00401947 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection | ||
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants | ||
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | ||
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | ||
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT04422431 | Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 | ||
| NCT03551730 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4) | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants | ||
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT07732361 | A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT). | ||
| NCT01567085 | Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor | ||
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | ||
| NCT02273596 | Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | ||
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy | ||
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | ||
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab |
